Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE006 (GBR) (Dr. Rossi)
· consented 2022-07-06
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
assessed
2026-08-18
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-02 (study day 18); relationship: Y
severe
assessed
2026-08-18
Grade 3 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 109); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 170); relationship: N
severe
serious
assessed
2026-08-18
Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-06-05 (study day 691); relationship: N; serious criteria: hospitalization
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-11-03 (study day 842); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.